AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 11939912 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 3045
Study 10490723 — intervention group
Group type: EXPERIMENTAL
Intervention: G‐CSF started on day 0 (day 0 group)
Number of subjects: 60
Study 10490723 — intervention group
Group type: COMPARATOR
Intervention: G‐CSF started on day 5 (day 5 group)
Number of subjects: 60
Study 9168671 — intervention group
Group type: COMPARATOR
Intervention: AgNORs counts in normal specimens
Number of subjects: 0
Study 9168671 — intervention group
Group type: EXPERIMENTAL
Intervention: AgNORs counts in mild dysplasia
Number of subjects: 0
Study 9168671 — intervention group
Group type: EXPERIMENTAL
Intervention: AgNORs counts in moderate dysplasia
Number of subjects: 0
Study 9168671 — intervention group
Group type: EXPERIMENTAL
Intervention: AgNORs counts in severe dysplasia
Number of subjects: 0
Study 9168671 — intervention group
Group type: EXPERIMENTAL
Intervention: AgNORs counts in carcinoma in situ
Number of subjects: 0
Study 9168671 — intervention group
Group type: EXPERIMENTAL
Intervention: AgNORs counts in glandular extensions of carcinoma in situ
Number of subjects: 0
Study 1748141 — intervention group
Group type: EXPERIMENTAL
Intervention: Org 10172 (bolus injection of 3250 anti‐Xa units)
Number of subjects: 6
Study 1748141 — intervention group
Group type: EXPERIMENTAL
Intervention: Digoxin (0.25 mg once daily for 8 days)
Number of subjects: 6
Study 1748141 — intervention group
Group type: EXPERIMENTAL
Intervention: Org 10172 and Digoxin combination
Number of subjects: 6
Study 6803946 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral cholecystography
Number of subjects: 25
Study 6803946 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasonography
Number of subjects: 25
Study 6803946 — intervention group
Group type: EXPERIMENTAL
Intervention: Repeat oral cholecystography
Number of subjects: 25
Study 30414822 — intervention group
Group type: EXPERIMENTAL
Intervention: 10-week instructor-led resistance training program
Number of subjects: 70
Study 28720139 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of intramuscular/intra-articular prednisolone, methotrexate (MTX), and golimumab (GOL) for 24 weeks
Number of subjects: 88
Study 28720139 — intervention group
Group type: COMPARATOR
Intervention: Combination of intramuscular/intra-articular prednisolone, methotrexate (MTX), and placebo for 24 weeks
Number of subjects: 88
Study 26829760 — intervention group
Group type: EXPERIMENTAL
Intervention: Manual Lymphatic Drainage (MLD) treatments (5 sessions)
Number of subjects: 60
Study 26829760 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 60
Study 24355210 — intervention group
Group type: COMPARATOR
Intervention: Bevacizumab
Number of subjects: 0
Study 24355210 — intervention group
Group type: COMPARATOR
Intervention: Cediranib
Number of subjects: 0
Study 21371166 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine (0.5 μg·kg(‐1))
Number of subjects: 60
Study 21371166 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam (0.1 mg·kg(‐1))
Number of subjects: 60
Study 19098058 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate PCI
Number of subjects: 251
Study 19098058 — intervention group
Group type: COMPARATOR
Intervention: Deferred PCI
Number of subjects: 251
Study 17874530 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose fixed combination of perindopril and indapamide
Number of subjects: 11140
Study 17874530 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive gliclazide-MR-based regimen targeting HbA(1c) levels of 6.5% or less
Number of subjects: 11140
Study 17874530 — intervention group
Group type: COMPARATOR
Intervention: Standard therapy for blood glucose control
Number of subjects: 11140
Study 14687174 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose octreotide
Number of subjects: 15
Study 14687174 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose octreotide
Number of subjects: 15
Study 14687174 — intervention group
Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 15
Study 14687174 — intervention group
Group type: COMPARATOR
Intervention: Repetitive high-pressure mechanical sigmoid stimulation
Number of subjects: 15
Study 14687174 — intervention group
Group type: EXPERIMENTAL
Intervention: Octreotide (during repetitive sigmoid stimulation)
Number of subjects: 15
Study 11758266 — intervention group
Group type: EXPERIMENTAL
Intervention: Buffered lidocaine
Number of subjects: 42
Study 11758266 — intervention group
Group type: EXPERIMENTAL
Intervention: EMLA cream
Number of subjects: 42
Study 11758266 — intervention group
Group type: COMPARATOR
Intervention: No anesthetic (Control group)
Number of subjects: 42
Study 9223108 — intervention group
Group type: EXPERIMENTAL
Intervention: Stimulation with PMA
Number of subjects: 2
Study 9223108 — intervention group
Group type: EXPERIMENTAL
Intervention: Stimulation with H2O2
Number of subjects: 2
Study 9223108 — intervention group
Group type: EXPERIMENTAL
Intervention: Stimulation with FMLP
Number of subjects: 2
Study 9223108 — intervention group
Group type: EXPERIMENTAL
Intervention: Stimulation with GSH
Number of subjects: 2
Study 9223108 — intervention group
Group type: EXPERIMENTAL
Intervention: Stimulation with GM-CSF
Number of subjects: 2
Study 9223108 — intervention group
Group type: EXPERIMENTAL
Intervention: Stimulation with IL-2
Number of subjects: 2
Study 9223108 — intervention group
Group type: EXPERIMENTAL
Intervention: Stimulation with LPS
Number of subjects: 2
Study 9223108 — intervention group
Group type: COMPARATOR
Intervention: No stimulation
Number of subjects: 2
Study 7967758 — intervention group
Group type: EXPERIMENTAL
Intervention: Back-strengthening exercise
Number of subjects: 60
Study 7967758 — intervention group
Group type: COMPARATOR
Intervention: Control group (no exercise prescription)
Number of subjects: 60
Study 3632149 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapeutic drug monitoring program for digoxin
Number of subjects: 207
Study 3632149 — intervention group
Group type: COMPARATOR
Intervention: Withdrawal of therapeutic drug monitoring program
Number of subjects: 207
Study 30530584 — intervention group
Group type: EXPERIMENTAL
Intervention: In vitro maturation (IVM)
Number of subjects: 0
Study 30530584 — intervention group
Group type: COMPARATOR
Intervention: In vitro fertilisation (IVF)
Number of subjects: 0
Study 30530584 — intervention group
Group type: EXPERIMENTAL
Intervention: IVM and IVF
Number of subjects: 0
Study 26644536 — intervention group
Group type: EXPERIMENTAL
Intervention: Cetuximab (CTX) 400 mg/m2 as loading dose followed by 250 mg/m2 once per week with radiotherapy (RT)
Number of subjects: 70
Study 26644536 — intervention group
Group type: COMPARATOR
Intervention: Cisplatin (CDDP) 40 mg/m2 once per week with radiotherapy (RT)
Number of subjects: 70
Study 26644536 — intervention group
Group type: EXPERIMENTAL
Intervention: Cetuximab (CTX) with radiotherapy (RT)
Number of subjects: 70
Study 26644536 — intervention group
Group type: COMPARATOR
Intervention: Cisplatin (CDDP) with radiotherapy (RT)
Number of subjects: 70
Study 24549933 — intervention group
Group type: EXPERIMENTAL
Intervention: 13.3 mg/24 h rivastigmine patch
Number of subjects: 567
Study 24549933 — intervention group
Group type: COMPARATOR
Intervention: 9.5 mg/24 h rivastigmine patch
Number of subjects: 567
Study 23250170 — intervention group
Group type: EXPERIMENTAL
Intervention: Single bond total-etch adhesive (3M ESPE, USA)
Number of subjects: 77
Study 23250170 — intervention group
Group type: EXPERIMENTAL
Intervention: UniFil bond self-etch primer (GC, Tokyo, Japan)
Number of subjects: 77
Study 23250170 — intervention group
Group type: EXPERIMENTAL
Intervention: Single bond total-etch adhesive (3M ESPE, USA) with blotting and primer application
Number of subjects: 77
Study 23250170 — intervention group
Group type: EXPERIMENTAL
Intervention: UniFil bond with repriming treatment (UF-V and UF-VI)
Number of subjects: 77
Study 20204691 — intervention group
Group type: EXPERIMENTAL
Intervention: Digestive enzyme supplementation
Number of subjects: 43
Study 20204691 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 43
Study 17661864 — intervention group
Group type: EXPERIMENTAL
Intervention: Dextromethorphan (DEX) 30 mg tablets, administered preoperatively and three times in the first 24 hours post-surgery.
Number of subjects: 100
Study 17661864 — intervention group
Group type: COMPARATOR
Intervention: Placebo (P), administered following the same schedule as DEX.
Number of subjects: 100
Study 16055276 — intervention group
Group type: EXPERIMENTAL
Intervention: GRACE tool
Number of subjects: 72
Study 16055276 — intervention group
Group type: COMPARATOR
Intervention: Nurse counseling
Number of subjects: 72
Study 12373614 — intervention group
Group type: EXPERIMENTAL
Intervention: Rye bread high in phloem (HP, 14% of rye flour substituted with phloem powder)
Number of subjects: 75
Study 12373614 — intervention group
Group type: EXPERIMENTAL
Intervention: Rye bread low in phloem (LP, 7% of rye flour substituted with phloem powder)
Number of subjects: 75
Study 12373614 — intervention group
Group type: COMPARATOR
Intervention: Placebo rye bread
Number of subjects: 75
Study 9989683 — intervention group
Group type: EXPERIMENTAL
Intervention: High-oleate meal (50 g)
Number of subjects: 69
Study 9989683 — intervention group
Group type: EXPERIMENTAL
Intervention: High-palmitate meal (50 g)
Number of subjects: 69
Study 9989683 — intervention group
Group type: COMPARATOR
Intervention: Low-fat meal (15 g high-oleate oil)
Number of subjects: 69
Study 9989683 — intervention group
Group type: EXPERIMENTAL
Intervention: Fasting FVIIc and FVIIa concentrations in RQ genotype
Number of subjects: 69
Study 9989683 — intervention group
Group type: EXPERIMENTAL
Intervention: Postprandial response in both RQ and RR genotypes
Number of subjects: 69
Study 7582157 — intervention group
Group type: EXPERIMENTAL
Intervention: Local Intranasal Immunotherapy (LII) with macronized powder Parietaria officinalis pollen in increasing doses
Number of subjects: 20
Study 7582157 — intervention group
Group type: COMPARATOR
Intervention: Control group (5 patients)
Number of subjects: 20
Study 2329484 — intervention group
Group type: EXPERIMENTAL
Intervention: Immersion technique
Number of subjects: 159
Study 2329484 — intervention group
Group type: COMPARATOR
Intervention: Applanation technique
Number of subjects: 159
Study 2329484 — intervention group
Group type: COMPARATOR
Intervention: Modified applanation technique
Number of subjects: 159
Study 2329484 — intervention group
Group type: EXPERIMENTAL
Intervention: Cataract patients
Number of subjects: 159
Study 2329484 — intervention group
Group type: COMPARATOR
Intervention: Healthy young eyes
Number of subjects: 159
Study 367655 — intervention group
Group type: EXPERIMENTAL
Intervention: Imipramine (10-20 mg)
Number of subjects: 14
Study 367655 — intervention group
Group type: COMPARATOR
Intervention: Scopolamine butylbromide (10-20 mg)
Number of subjects: 14
Study 31786747 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-setup of home respiratory polygraphy (HRP)
Number of subjects: 301
Study 31786747 — intervention group
Group type: COMPARATOR
Intervention: Nurse intervention for home respiratory polygraphy (HRP)
Number of subjects: 301
Study 31786747 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-setup of HRP
Number of subjects: 301
Study 31786747 — intervention group
Group type: COMPARATOR
Intervention: Nurse setup of HRP
Number of subjects: 301
Study 31711244 — intervention group
Group type: EXPERIMENTAL
Intervention: CD+PET/US
Number of subjects: 34
Study 31711244 — intervention group
Group type: COMPARATOR
Intervention: CD only
Number of subjects: 34
Study 27324724 — intervention group
Group type: EXPERIMENTAL
Intervention: Black tea tablet + standard treatment
Number of subjects: 120
Study 27324724 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment
Number of subjects: 120
Study 25262677 — intervention group
Group type: EXPERIMENTAL
Intervention: Water jet device containing chlorhexidine gel (Silonite®) for home use twice daily
Number of subjects: 39
Study 25262677 — intervention group
Group type: COMPARATOR
Intervention: Control group with recommended oral hygiene measures without water jet usage
Number of subjects: 39
Study 25262677 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 39
Study 23592677 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral Activation (BA)
Number of subjects: 148
Study 23592677 — intervention group
Group type: COMPARATOR
Intervention: Lifestyle Intervention (LI)
Number of subjects: 148
Study 21908036 — intervention group
Group type: EXPERIMENTAL
Intervention: Dalcetrapib 600 mg/day for 24 months
Number of subjects: 130
Study 21908036 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 24 months
Number of subjects: 130
Study 19264836 — intervention group
Group type: EXPERIMENTAL
Intervention: Hepatitis B vaccine administered at 0, 6 and 14 weeks
Number of subjects: 74
Study 19264836 — intervention group
Group type: COMPARATOR
Intervention: Hepatitis B vaccine administered at 6, 10 and 14 weeks
Number of subjects: 74
Study 16174858 — intervention group
Group type: EXPERIMENTAL
Intervention: Estrogen-plus-progestin therapy (0.625 mg conjugated equine estrogens + 2.5 mg medroxyprogesterone acetate)
Number of subjects: 413
Study 16174858 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 413
Study 11823394 — intervention group
Group type: EXPERIMENTAL
Intervention: Tramadol 100 mg with lidocaine 0.5% (3 mg.kg(‐1))
Number of subjects: 30
Study 11823394 — intervention group
Group type: COMPARATOR
Intervention: Isotonic saline (Control Group C)
Number of subjects: 30
Study 10516413 — intervention group
Group type: EXPERIMENTAL
Intervention: Losartan
Number of subjects: 100
Study 10516413 — intervention group
Group type: COMPARATOR
Intervention: Captopril
Number of subjects: 100
Study 7721498 — intervention group
Group type: EXPERIMENTAL
Intervention: Bisoprolol 10 mg once daily
Number of subjects: 30
Study 7721498 — intervention group
Group type: COMPARATOR
Intervention: Isosorbide dinitrate 20 mg three times daily
Number of subjects: 30
Study 2248921 — intervention group
Group type: EXPERIMENTAL
Intervention: DexSol containing recombinant hEGF and human insulin
Number of subjects: 105
Study 2248921 — intervention group
Group type: COMPARATOR
Intervention: DexSol (CSM with 1% dextran)
Number of subjects: 105
Study 2248921 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 105
Study 6113234 — intervention group
Group type: EXPERIMENTAL
Intervention: Prazeapm
Number of subjects: 0
Study 6113234 — intervention group
Group type: EXPERIMENTAL
Intervention: Diazepam
Number of subjects: 0
Study 6113234 — intervention group
Group type: EXPERIMENTAL
Intervention: Lorazepam
Number of subjects: 0
Study 6113234 — intervention group
Group type: EXPERIMENTAL
Intervention: Placebo
Number of subjects: 0
Study 6113234 — intervention group
Group type: EXPERIMENTAL
Intervention: All treatments (Prazeapm, Diazepam, Lorazepam, Placebo)
Number of subjects: 0
Study 30622223 — intervention group
Group type: EXPERIMENTAL
Intervention: Group LB: 20 ml 0.25% levobupivacaine + 0.3 mg (1 ml) buprenorphine
Number of subjects: 93
Study 30622223 — intervention group
Group type: EXPERIMENTAL
Intervention: Group LD: 20 ml 0.25% levobupivacaine + 4 mg (1 ml) dexamethasone
Number of subjects: 93
Study 30622223 — intervention group
Group type: COMPARATOR
Intervention: Group L: 20 ml 0.25% levobupivacaine + 1 ml normal saline (NS)
Number of subjects: 93
Study 28640161 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravaginal 0.50% (6.5 mg) prasterone
Number of subjects: 696
Study 28640161 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 696
Study 25489056 — intervention group
Group type: EXPERIMENTAL
Intervention: Canned beverages
Number of subjects: 60
Study 25489056 — intervention group
Group type: COMPARATOR
Intervention: Glass bottled beverages
Number of subjects: 60
Study 22381828 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute normovolemic hemodilution (ANH)
Number of subjects: 100
Study 22381828 — intervention group
Group type: COMPARATOR
Intervention: Control (standard anesthetic management)
Number of subjects: 100
Study 19679575 — intervention group
Group type: EXPERIMENTAL
Intervention: Custom-made, semirigid running shoe orthoses
Number of subjects: 51
Study 19679575 — intervention group
Group type: COMPARATOR
Intervention: Control group (regular training activity without treatment)
Number of subjects: 51
Study 19853886 — intervention group
Group type: EXPERIMENTAL
Intervention: Home remediation
Number of subjects: 117
Study 16754934 — intervention group
Group type: EXPERIMENTAL
Intervention: Epirubicin, bleomycin, vinblastine, and prednisone (EBVP) followed by involved-field radiotherapy (IF-RT) in favorable patients
Number of subjects: 722
Study 16754934 — intervention group
Group type: EXPERIMENTAL
Intervention: MOPP/ABV hybrid followed by IF-RT in unfavorable patients
Number of subjects: 722
Study 16754934 — intervention group
Group type: COMPARATOR
Intervention: Epirubicin, bleomycin, vinblastine, and prednisone (EBVP) followed by IF-RT in unfavorable patients
Number of subjects: 722
Study 16754934 — intervention group
Group type: COMPARATOR
Intervention: Subtotal nodal irradiation (STNI) in favorable patients
Number of subjects: 722
Study 16133950 — intervention group
Group type: EXPERIMENTAL
Intervention: Late evidence disclosure
Number of subjects: 116
Study 16133950 — intervention group
Group type: COMPARATOR
Intervention: Early evidence disclosure
Number of subjects: 116
Study 12353677 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5% fluorouracil cream for 1 week
Number of subjects: 177
Study 12353677 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5% fluorouracil cream for 2 weeks
Number of subjects: 177
Study 12353677 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5% fluorouracil cream for 4 weeks
Number of subjects: 177
Study 12353677 — intervention group
Group type: COMPARATOR
Intervention: Vehicle (control)
Number of subjects: 177
Study 10407503 — intervention group
Group type: EXPERIMENTAL
Intervention: Antioxidant vitamins (150 mg ascorbic acid, 67 mg alpha-tocopherol, 9 mg beta-carotene)
Number of subjects: 132
Study 10407503 — intervention group
Group type: COMPARATOR
Intervention: B group vitamins (1 mg folic acid, 7.2 mg pyridoxine, 0.02 mg cyanocobalamin)
Number of subjects: 132
Study 10407503 — intervention group
Group type: EXPERIMENTAL
Intervention: B group vitamins with antioxidant vitamins
Number of subjects: 132
Study 10407503 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 132
Study 7554453 — intervention group
Group type: EXPERIMENTAL
Intervention: IMREG-1 plus antigen
Number of subjects: 0
Study 7554453 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus antigen
Number of subjects: 0
Study 7554453 — intervention group
Group type: COMPARATOR
Intervention: Antigen alone (control)
Number of subjects: 0
Study 2210893 — intervention group
Group type: EXPERIMENTAL
Intervention: Gallium-67 imaging
Number of subjects: 44
Study 2210893 — intervention group
Group type: EXPERIMENTAL
Intervention: Immunosuppressive therapy
Number of subjects: 44
Study 6113858 — intervention group
Group type: EXPERIMENTAL
Intervention: 60 mg terfenadine suspension
Number of subjects: 14
Study 6113858 — intervention group
Group type: EXPERIMENTAL
Intervention: 180 mg terfenadine suspension
Number of subjects: 14
Study 6113858 — intervention group
Group type: EXPERIMENTAL
Intervention: 60 mg of 14C terfenadine
Number of subjects: 14
Study 6113858 — intervention group
Group type: EXPERIMENTAL
Intervention: Urinary excretion of 14C
Number of subjects: 14
Study 6113858 — intervention group
Group type: EXPERIMENTAL
Intervention: Fecal recovery of 14C
Number of subjects: 14
Study 30892616 — intervention group
Group type: EXPERIMENTAL
Intervention: Automated text-messaging support (SmokefreeTXT) plus personalized texts from a peer mentor
Number of subjects: 200
Study 30892616 — intervention group
Group type: COMPARATOR
Intervention: Automated text-messaging support (SmokefreeTXT)
Number of subjects: 200
Study 31079480 — intervention group
Group type: EXPERIMENTAL
Intervention: Life review intervention
Number of subjects: 46
Study 31079480 — intervention group
Group type: COMPARATOR
Intervention: Control group (no life review)
Number of subjects: 46
Study 28849773 — intervention group
Group type: EXPERIMENTAL
Intervention: Double dose (20 µg) hepatitis B vaccine
Number of subjects: 55
Study 28849773 — intervention group
Group type: COMPARATOR
Intervention: Standard dose (10 µg) hepatitis B vaccine
Number of subjects: 55
Study 25670366 — intervention group
Group type: EXPERIMENTAL
Intervention: Anacetrapib (150 and 300 mg/d)
Number of subjects: 0
Study 25670366 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin (20 mg/d)
Number of subjects: 0
Study 25670366 — intervention group
Group type: EXPERIMENTAL
Intervention: Anacetrapib + Atorvastatin
Number of subjects: 0
Study 25670366 — intervention group
Group type: COMPARATOR
Intervention: Atorvastatin alone vs placebo
Number of subjects: 0
Study 24386975 — intervention group
Group type: EXPERIMENTAL
Intervention: Feedback to therapist (FbT)
Number of subjects: 475
Study 24386975 — intervention group
Group type: EXPERIMENTAL
Intervention: Feedback to therapist and patient (FbTP)
Number of subjects: 475
Study 24386975 — intervention group
Group type: COMPARATOR
Intervention: No feedback (NFb)
Number of subjects: 475
Study 22711385 — intervention group
Group type: EXPERIMENTAL
Intervention: Multivitamin, mineral and herbal supplement (Swisse Men's Ultivite®)
Number of subjects: 51
Study 22711385 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 51
Study 19031460 — intervention group
Group type: EXPERIMENTAL
Intervention: Quadruple ART (n = 43)
Number of subjects: 72
Study 19031460 — intervention group
Group type: EXPERIMENTAL
Intervention: Triple ART (n = 14)
Number of subjects: 72
Study 19031460 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual ART (n = 15)
Number of subjects: 72
Study 17376293 — intervention group
Group type: EXPERIMENTAL
Intervention: nateglinide (120 mg)
Number of subjects: 16
Study 17376293 — intervention group
Group type: COMPARATOR
Intervention: acarbose (50 mg)
Number of subjects: 16
Study 15199325 — intervention group
Group type: EXPERIMENTAL
Intervention: Withdrawal of non-nucleoside reverse transcriptase inhibitors (NNRTI) from current therapy
Number of subjects: 0
Study 15199325 — intervention group
Group type: COMPARATOR
Intervention: Non-nucleoside reverse transcriptase inhibitors (NNRTI)
Number of subjects: 0
Study 11772696 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine (60 mg/day)
Number of subjects: 150
Study 11772696 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 150
Study 9640894 — intervention group
Group type: EXPERIMENTAL
Intervention: Safety educational videotape
Number of subjects: 60
Study 9640894 — intervention group
Group type: EXPERIMENTAL
Intervention: Animated cartoon with incidental safety components
Number of subjects: 60
Study 9640894 — intervention group
Group type: COMPARATOR
Intervention: Edited cartoon program (omitting safety behavior scenes)
Number of subjects: 60
Study 8078734 — intervention group
Group type: EXPERIMENTAL
Intervention: Open label IVIG
Number of subjects: 148